https://www.thebodypro.com/author/polly-clayden

Latest by Polly Clayden

VRC01 in HIV-Exposed Newborns: First Results Support Monthly Injections for Those at Risk Through Breastfeeding Img
CROI (Conference on Retroviruses and Opportunistic Infections)

VRC01 in HIV-Exposed Newborns: First Results Support Monthly Injections for Those at Risk Through Breastfeeding

Preliminary results suggest that VRC01 -- an investigational HIV neutralising monoclonal antibody -- administered subcutaneously to neonates is safe and well tolerated.

Raltegravir Pharmacokinetic Targets Met in High-Risk HIV-Exposed Infants Img
CROI (Conference on Retroviruses and Opportunistic Infections)

Raltegravir Pharmacokinetic Targets Met in High-Risk HIV-Exposed Infants

Daily raltegravir was safe and well tolerated at six weeks of life and met pharmacokinetic targets in HIV-exposed infants, according to data presented at CROI 2017.

Tenofovir Alafenamide Exposure Is Modestly Higher in Children Than Adults Img
CROI (Conference on Retroviruses and Opportunistic Infections)

Tenofovir Alafenamide Exposure Is Modestly Higher in Children Than Adults

Tenofovir alafenamide (TAF) and its metabolite tenofovir (TFV) exposures are slightly higher in children aged 6-12 years compared with adults.

Pre-ART Drug Resistance in Rural South Africa but Limited Clinical Impact With Good Adherence Img
CROI (Conference on Retroviruses and Opportunistic Infections)

Pre-ART Drug Resistance in Rural South Africa but Limited Clinical Impact With Good Adherence

The prevalence of transmitted drug resistance is above the WHO threshold of 5% in this study conducted in rural South Africa.

PREP in Pregnancy Does Not Increase Poor Birth Outcomes Img
CROI (Conference on Retroviruses and Opportunistic Infections)

PREP in Pregnancy Does Not Increase Poor Birth Outcomes

No increase in poor birth outcomes with PrEP used throughout pregnancy in the Partners Demonstration project.

Dose Reduction Potential of Nanoparticle ARV Formulations Confirmed in Humans Img
CROI (Conference on Retroviruses and Opportunistic Infections)

Dose Reduction Potential of Nanoparticle ARV Formulations Confirmed in Humans

First in-human trial results of nanoformulations of efavirenz and lopinavir confirmed the potential for a 50% dose reduction to the current standard oral dose of both antiretrovirals.

Significant Interaction Between Once-Weekly Isoniazid/Rifapentine and Daily Dolutegravir: Study Stopped Due to Toxicity Img
CROI (Conference on Retroviruses and Opportunistic Infections)

Significant Interaction Between Once-Weekly Isoniazid/Rifapentine and Daily Dolutegravir: Study Stopped Due to Toxicity

Serious toxicities were seen in participants in a drug-drug interaction study of once-weekly isoniazid and rifapentine with once-daily dolutegravir, leading to its early termination.

Increased Risk of IRIS With Integrase Inhibitors Reported in Two Studies Img
CROI (Conference on Retroviruses and Opportunistic Infections)

Increased Risk of IRIS With Integrase Inhibitors Reported in Two Studies

Two cohort studies presented at CROI 2017 showed a higher risk of IRIS with integrase inhibitor-based ART than with other regimens.

Fit for Purpose: Antiretroviral Treatment Optimization Img
CROI (Conference on Retroviruses and Opportunistic Infections)

Fit for Purpose: Antiretroviral Treatment Optimization

Launched at CROI 2017, this new edition of an annual i-Base publication reviews and updates current and planned research for treatment optimzation studies.

Pregnancy Common in ART Trials in Sub-Saharan Africa Despite Exclusion Criteria Img

Pregnancy Common in ART Trials in Sub-Saharan Africa Despite Exclusion Criteria

A new analysis reports that HIV-positive women in clinical trials in sub-Saharan Africa are likely to get pregnant as often as those receiving care outside of research settings.